SIBN News and Press, SI-BONE Inc. From 12/16/20

SANTA CLARA, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN) a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacro-pelvic anatomy, today announced that Humana has revised its coverage policies to cover minimally inv...

SI-BONE, Inc. (SIBN) Q3 2020 Earnings Conference Call November 02, 2020 4:30 PM ET Company Participants Matt Bacso - The Gilmartin Group Jeff Dunn - President & Chief Executive Officer Laura Francis - Chief Financial Officer & Chief Operating Officer Conference Call Participants David...

SI-BONE (SIBN): Q3 GAAP EPS of -$0.33 beats by $0.06.Revenue of $20.37M (+25.9% Y/Y) beats by $3.86M.2020 Guidance: Revenue to be in the range of $73-$74M, representing growth of ~8%-10% over 2019 revenue.Shares +0.48%.Press Release For further details see: SI-BONE EPS beats by $0.06, b...

SANTA CLARA, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2020. Recent Highlights ...

SANTA CLARA, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2020 after market close on Monda...

SI-BONE (SIBN) has priced its public offering of 3,190,053 shares of common stock, including 3M company's shares and 190,053 offered by a selling stockholder. common shares at $22.00/share, for expected gross proceeds of $66M to SI-BONE.Underwriters' over-allotment is an additional ...

SI-BONE (SIBN) commences an underwritten public offering of 3,190,053 common shares.Underwriters have a 30-day option to purchase up to an additional 478,507 common shares.Of the shares of common stock being offered, 3,000,000 shares are being offered by SI-BONE and 190,053 shares are being o...

SI-BONE (SIBN) preliminary and unaudited revenue for Q3 is expected to be in the range of $20.1M-20.4M, reflecting growth of 24%-26% compared to the prior year period.Q3 U.S. revenue expected $18.7M-18.9M, reflecting growth of 26%-27% compared to prior year. Q3 International revenue is e...

SANTA CLARA, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudited revenue for the three and nine months ended September 30, 2020. ...

SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that Jeffrey Dunn, Chairman and CEO, will host a virtual surgeon pan...